Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma

Journal of Immunotherapy

Volumn 35, Issue 2, 2012, Pages 159-168

  Ghazi, Alexia ^a,b   Ashoori, Aidin ^a,b   Hanley, Patrick J ^a,b   Brawley, Vita S ^a,b   Shaffer, Donald R ^a,b   Kew, Yvonne ^b   Powell, Suzanne Z ^b   Grossman, Robert ^b   Grada, Zakaria ^a,b   Scheurer, Michael E ^a,b   Hegde, Meenakshi ^a,b   Leen, Ann M ^a,b   Bollard, Catherine M ^a,b   Rooney, Cliona M ^a,b   Heslop, Helen E ^a,b   Gottschalk, Stephen ^a,b   Ahmed, Nabil ^a,b,c  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

CMV; GBM; glioblastoma; IE1; immunotherapy; pp65; T cells

Indexed keywords

ADENOVIRUS VECTOR; CYTOMEGALOVIRUS ANTIGEN PP65; GAMMA INTERFERON;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; BLOOD; BLOOD DONOR; CANCER PATIENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL EXPANSION; CELL THERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; POLYCLONAL ACTIVATION; PRIORITY JOURNAL; PROTEIN TARGETING; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM;

ADULT; AGED; ANTIGENS, VIRAL; BRAIN NEOPLASMS; CELL SEPARATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY, ADOPTIVE; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; T-LYMPHOCYTES;

EID: 84856845120     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318247642f     Document Type: Article

References (43)

1. Buckner JC. Factors influencing survival in high-grade gliomas. Semin Oncol. 2003;30:10-14. (Pubitemid 38199157)
2. Combs SE, Heeger S, Haselmann R, et al. Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)-phase I/II trial: Study protocol. BMC Cancer. 2006;6:133.
3. Stupp R, Mason WP, Van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996. (Pubitemid 40349501)
4. DeAngelis LM. Brain tumors.N Engl JMed. 2001;344:114-123. (Pubitemid 32052502)
5. Scheurer ME, Bondy ML, Aldape KD, et al. Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathol. 2008;116:79-86.
6. Mitchell DA, Xie W, Schmittling R, et al. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol. 2008;10:10-18. (Pubitemid 351250896)
7. Cobbs CS, Harkins L, Samanta M, et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 2002;62:3347-3350. (Pubitemid 34651375)
8. Lucas KG, Bao L, Bruggeman R, et al. The detection of CMV pp65 and IE1 in glioblastoma multiforme. J Neurooncol. 2011;103:231-238.
9. Straat K, Liu C, Rahbar A, et al. Activation of telomerase by human cytomegalovirus. J Natl Cancer Inst. 2009;101:488-497.
10. Cobbs CS. Evolving evidence implicates cytomegalovirus as a promoter of malignant glioma pathogenesis. Herpesviridae. 2011;2:10.
11. Soroceanu L, Matlaf L, Bezrookove V, et al. Human cytomegalovirus US28 found in glioblastoma promotes an invasive and angiogenic phenotype. Cancer Res. 2011;71:6643-6653.
12. Mitchell D, Archer GE, Bigner DD, et al. Efficacy of a phase II vaccine targeting Cytomegalovirus antigens in newly diagnosed GBM. J Clin Oncol. 2008;26:2042.
13. Bollard CM, Aguilar L, Straathof KC, et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med. 2004;200:1623-1633. (Pubitemid 40094186)
14. Heslop HE, Slobod KS, Pule MA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115:925-935.
15. Leen AM, Rooney CM, Foster AE. Improving T cell therapy for cancer. Annu Rev Immunol. 2007;25:243-265. (Pubitemid 46697909)
16. Lucas KG, Salzman D, Garcia A, et al. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease. Cancer. 2004;100:1892-1901. (Pubitemid 38529567)
17. Leen AM, Myers GD, Sili U, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006;12:1160-1166. (Pubitemid 44527351)
18. Bollard CM, Straathof K, Huls MH, et al. Cytotoxic T lymphocyte therapy for EBV positive Hodgkin's disease. Blood. 2003;102:901a.
19. Gottschalk S, Heslop H, Rooney C. Adoptive immunotherapy for EBV-associated malignancies. Leuk Lymphoma. 2005;46:1-10.
20. Louis CU, Straathof K, Bollard CM, et al. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother. 2010;33:983-990.
21. Scheurer ME, Bondy ML, Aldape KD, et al. Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathol. 2008;116:79-86.
22. Ahmed N, Salsman VS, Kew Y, et al. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res. 2010;16: 474-485.
23. Fujita Y, Leen AM, Sun J, et al. Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy. J Immunother. 2008;31:665-674.
24. Hanley PJ, Shaffer DR, Cruz CR, et al. Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation. Cytotherapy. 2011;13:976-986.
25. Mitchell DA, Xie W, Schmittling R, et al. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol. 2008;10: 10-18. (Pubitemid 351250896)
26. Papagno L, Almeida JR, Nemes E, et al. Cell permeabilization for the assessment of T lymphocyte polyfunctional capacity. J Immunol Methods. 2007;328:182-188. (Pubitemid 350017756)
27. Harari A, Enders FB, Cellerai C, et al. Distinct profiles of cytotoxic granules in memory CD8 T cells correlate with function, differentiation stage, and antigen exposure. J Virol. 2009;83:2862-2871.
28. Cheung AK, Abendroth A, Cunningham AL, et al. Viral gene expression during the establishment of human cytomegalovirus latent infection in myeloid progenitor cells. Blood. 2006;108: 3691-3699. (Pubitemid 44864546)
29. Dziurzynski K, Wei J, Qiao W, et al. Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype. Clin Cancer Res. 2011;17: 4642-4649.
30. Waziri A. Glioblastoma-derived mechanisms of systemic immunosuppression. Neurosurg Clin N Am. 2010;21:31-42.
31. Avril T, Vauleon E, Tanguy-Royer S, et al. Mechanisms of immunomodulation in human glioblastoma. Immunotherapy. 2011;3:42-44.
32. Gustafson MP, Lin Y, New KC, et al. Systemic immune suppression in glioblastoma: The interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone. Neuro Oncol. 2010;12:631-644.
33. Sippel TR, White JT, Nag K, et al. Neutrophil degranulation and immunosuppression in patients with glioblastoma: Restoration of cellular immune function by targeting arginase I. Clin Cancer Res. 2011;17:6992-7002.
34. Gandhi MK, Lambley E, Duraiswamy J, et al. Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients. Blood. 2006;108: 2280-2289. (Pubitemid 44497511)
35. Gilbert MJ, Riddell SR, Plachter B, et al. Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product. Nature. 1996;383:720-722. (Pubitemid 26360648)
36. Jones TR, Hanson LK, Sun L, et al. Multiple independent loci within the human cytomegalovirus unique short region downregulate expression of major histocompatibility complex class I heavy chains. J Virol. 1995;69:4830-4841.
37. Horn B, Bao L, Dunham K, et al. Infusion of cytomegalovirus specific cytotoxic T lymphocytes from a sero-negative donor can facilitate resolution of infection and immune reconstitution. Pediatr Infect Dis J. 2009;28:65-67.
38. Bunde T, Kirchner A, Hoffmeister B, et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J ExpMed. 2005;201:1031-1036. (Pubitemid 40524670)
39. Liao X, Li Y, Bonini C, et al. Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of highaffinity tumor-reactive cytotoxic T lymphocytes. Mol Ther. 2004;9:757-764. (Pubitemid 38660429)
40. Bollard CM, Gottschalk S, Leen AM, et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 2007;110:2838-2845. (Pubitemid 350006936)
41. Heslop HE, Slobod KS, Pule MA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115:925-935.
42. Prins RM, Cloughesy TF, Liau LM. Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N Engl J Med. 2008;359:539-541.
43. Prins RM, Soto H, Konkankit V, et al. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res. 2011;17:1603-1615.